ARIEL3

Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Patients with Platinum-Sensitive Relapsed High-Grade Serous and Endometrioid Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

RUCAPARIB

Rucaparib is an oral, small-molecule PARP inhibitor.

Please visit ClinicalTrials.gov for more information on this trial (NCT01968213).

ARIEL3 is sponsored by Clovis Oncology, Inc, Boulder, CO, USA

ARIEL3 Trial Schema



*Disease progression (RECIST v1.1) as assessed by investigator or death from any cause

PARP=poly ADP ribose polymerase, HRD=homologous recombination deficiency, NGS=next-generation sequencing, LOH=loss of heterozygosity, RECIST=Response Evaluation Criteria in Solid Tumors, CR=complete response, PR=partial response, GCIG=Gynecologic Cancer Intergroup, CA-125=cancer antigen 125, CT=computerized tomography, PRO=patient-reported outcome, FOSI-18=FACT Ovarian Symptom Index-18, PFS=progression-free survival, OS=overall survival, PK=pharmacokinetics

Key Eligibility Criteria:

- Confirmed diagnosis of high-grade serous or endometrioid epithelial ovarian, primary peritoneal, or fallopian tube cancer
- Received ≥2 prior platinum-based treatment regimens including platinum-based regimen that must have been administered immediately prior to maintenance therapy in this trial
- Received no more than 1 non-platinum chemotherapy regimen. Prior hormonal therapy will not be counted as a non-platinum regimen
- Sufficient archival tumor tissue for analysis
- No prior treatment with any PARP inhibitor, including rucaparib; patients who received prior iniparib are eligible
- No history of prior cancer except for non-melanoma skin cancer, breast cancer curatively >3 years ago, curatively treated solid tumor, and synchronous endometrial cancer (Stage 1A) with ovarian cancer
- No untreated or symptomatic central nervous system metastases

ARIEL3
Assessment of Rucaparib in ovarian cancER: phase 3 trial